Product Name:
NAD+ 500 (Nicotinamide Adenine Dinucleotide)
Chemical Information:
- Molecular Formula: C21H27N7O14P2
- Molecular Weight: 663.43 g/mol
- Form: Lyophilized Powder
- Structure: Coenzyme composed of two nucleotides joined by their phosphate groups
Description:
NAD+ (Nicotinamide Adenine Dinucleotide) is a naturally occurring coenzyme found in all living cells. It plays a critical role in cellular redox reactions, acting as a key electron transporter in metabolic pathways such as glycolysis, the TCA cycle, and oxidative phosphorylation.
In recent years, NAD+ has gained significant attention in scientific research for its potential to enhance mitochondrial health, improve cognitive performance, and slow cellular aging. NAD+ 500 is provided in high-purity lyophilized form for research focused on energy metabolism, neurodegeneration, and sirtuin activation.
Research Applications:
NAD+ 500 is widely used in biomedical and anti-aging research for:
- Mitochondrial Function: Supporting studies on cellular respiration and ATP synthesis.
- Neuroprotection: Exploring roles in brain energy metabolism and age-related cognitive decline.
- Longevity Research: Investigating sirtuin-mediated pathways and DNA repair mechanisms.
- Metabolic Health: Assessing NAD+ levels in insulin sensitivity, inflammation, and metabolic disorders.
- Circadian Rhythm Regulation: Studying its involvement in sleep-wake cycle and biological clock modulation.
Storage and Handling:
- Store lyophilized powder at –20°C in a dry, light-protected environment.
- Reconstitute with bacteriostatic water at 2–8°C and use promptly.
- Avoid contamination and repeated freeze-thaw cycles.
Product Specifications:
- Purity: ≥99% (HPLC Verified)
- Appearance: White crystalline lyophilized powder
- Solubility: Fully soluble in bacteriostatic water or PBS (pH 7.4)
Important Note:
NAD+ 500 IS FOR RESEARCH USE ONLY.
It is not intended for human or veterinary use. Misuse of this product may violate local laws and institutional policies.
Reviews
There are no reviews yet.